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Virus-like particlesa b s t r a c t
Enterotoxigenic Escherichia coli (ETEC) causes diarrhoea by secreting enterotoxins into the small intes-
tine. Human ETEC strains may secrete any combination of three enterotoxins: the heat-labile toxin
(LT) and the heat-stable toxins (ST), of which there are two variants, called human ST (STh) and porcine
ST (STp). Strains expressing STh, either alone or in combination with LT and/or STp, are among the four
most important diarrhoea-causing pathogens affecting children in low- and middle-income countries. ST
is therefore an attractive target for ETEC vaccine development. To produce a safe ST-based vaccine, sev-
eral challenges must be solved. ST must be rendered immunogenic and non-toxic, and antibodies elicited
by an ST vaccine should neutralize ST but not cross-react with the endogenous ligands uroguanylin and
guanylin. Virus-like particles (VLPs) tend to be highly immunogenic and are increasingly being used as
carriers for presenting heterologous antigens in new vaccines. In this study, we have coupled native
STh and the STh-A14T toxoid to the coat protein of Acinetobacter phage AP205 by using the
SpyCatcher system and immunized mice with these VLPs without the use of adjuvants. We found that
both STs were efficiently coupled to the VLP, that both the STh and STh-A14T VLPs were immunogenic
in mice, and that the resulting serum antibodies could completely neutralize the toxic activities of native
STh. The serum antibodies showed a high degree of immunological cross-reaction to STp, while there was
little or no unwanted cross-reaction to uroguanylin and guanylin. Moreover, compared to native STh, the
STh-A14T mutation did not seem to negatively impact the immunogenicity of the construct or the neu-
tralizing ability of the resulting sera. Taken together, these findings demonstrate that VLPs are suitable
carriers for making STs immunogenic, and that the STh-A14T-coupled AP205 VLP represents a promising
ETEC vaccine candidate.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction drenmore vulnerable to other serious infections [7]. ETEC’s negativeDiarrheal diseases caused by infections with enterotoxigenic
Escherichia coli (ETEC) is a major contributor to health problems
among young children living in low- and middle-income countries
(LMICs) [1–5] and for travellers visiting these countries [6]. Diar-
rhoea may lead to malnutrition in young children, especially when
they experience repeated or prolonged diarrhoeal episodes. ETEC
contributes to this child undernutrition, which in turn makes chil-impact on global health and its consequent negative economic
impact suggest that a vaccine against ETEC should be prioritized
[8,9]. To date no ETEC-specific vaccines are available [10].
ETEC is predominantly transmitted through faecal contamina-
tion of food and water [11]. Following oral ingestion, ETEC
colonizes the small intestine, and diarrhoea is induced by the
secretion of one, two, or all of three different enterotoxins: the
heat-labile enterotoxin (LT), the human heat-stable enterotoxin
(STh), and the porcine heat-stable enterotoxin (STp) [11]. STh
and STp are 18 and 19 amino acid peptides, respectively, and they
are 78% identical [12]. ETEC strains secreting STh are among the
four most important pathogens associated with moderate-to-
severe diarrhoea in LMIC children [13], making STh one of the most
attractive targets for ETEC vaccine development.
STh and STp, which are commonly referred to as ST, bind to and
activate the transmembrane guanylyl cyclase C (GC-C) receptor,
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vation of the GC-C receptor triggers a signalling cascade which ulti-
mately causes diarrhoea through the release of electrolytes and
water into the gut lumen [14,15]. The ST peptides have three con-
served disulfide bridges which are crucial for structural integrity
and toxicity [12]. Three key challenges must be solved to succeed
in making safe ST-based vaccines [12,16]. Firstly, STs are non-
immunogenic due to their small size, and they must therefore be
made immunogenic by coupling to an immunogenic carrier. Sec-
ondly, STs are potent toxins and must be made non-toxic. Finally,
STs are similar to the endogenous GC-C receptor peptides guanylin
and uroguanylin both in sequence and structure, and ST epitopes
that induce unwanted immunological cross-reactions to these
two ligands must, therefore, be altered [12,17–19]. To identify
STh mutants with reduced or abolished toxicity, but with retained
antigenicity allowing recognition by neutralizing anti-ST antibod-
ies, we recently screened a library of all possible 361 single-
amino acid STh mutants [18]. This screening led to the identifica-
tion of our current lead ST toxoid candidate STh-A14T which has
>800-fold lower toxicity than native STh, but which retains most
epitopes that are needed to effectively induce a neutralizing anti-
ST immune response [20].
Previously, ST has been rendered immunogenic mainly through
coupling to protein carriers [12], but also through polymerization
[21] and by coupling to T-helper cell epitopes bound to lipopeptide
adjuvants [22]. An alternative and promisingway of rendering small
peptides immunogenic is to couple them to virus-like particles
(VLPs) which are self-assembled viral envelope or capsid proteins
[23,24]. Antigens can be presented on the VLP surface by the means
of genetic fusions, enzymatic linkage, or chemical conjugation [24].
VLPs have ordered surfaces which allows for high density presenta-
tion of single, multivalent, or combinatorial antigens [25–28] and
this orderly presentation of vaccine epitopes leads to more defined
interactions with the immune system compared to when they are
conjugated to the surface of regular single-protein carriers [29].
VLPs are also promising in terms of yielding highly stable and
efficient vaccines [30]. VLP-based vaccines targeting Hepatitis B
(HBV), Hepatitis E (HBE), and human papilloma virus (HPV) have
already been approved for human use [31]. A large number of VLP-
based vaccines are also being developed for bacterial and viral dis-
eases, where the VLPs are either derived from the pathogens they
are intended to protect against or they are used as carriers for pre-
senting heterologous antigens [29,32,33]. A simple system that
allows for spontaneous and irreversible in vitro conjugation of
heterologous antigens to VLP surfaces has recently been described
[34–36]. In this system, conjugation is facilitated by an isopeptide
bond formed between an aspartic acid in the SpyTag polypeptide
and a lysine in the SpyCatcher domain [34]. The SpyCatcher/Tag sys-
tem has been used, in different configurations, to display malaria
antigens on the Acinetobacter phage AP205 VLP surface [35,36].
In this study, we investigated the suitability of using the
SpyCatcher-AP205 VLP system to render STh immunogenic,
assessed the ability of the non-toxic STh-A14T mutant to elicit
STh-neutralizing antibodies in mice, and we investigated the
degree of cross-reactivity the serum antibodies had towards STp,
guanylin, and uroguanylin.2. Materials and methods
2.1. Cloning, expression, and purification of SpyTag-STh fusion
peptides
To facilitate coupling to SpyCatcher-AP205 VLPs, we genetically
fused the SpyTag to the N-terminus of native STh and STh-A14T,
separated by a linker (Fig. 1A). The previously described pET-DsbC-STh and pET-DsbC-STh-A14T expression vectors [20] were
used as backbones, and the insertions were accomplished using
the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Ips-
wich, MA, USA), and the primers SpyT_lnk_STh_F: 50-caaatgggg
cagtggtggttcagggggttccggtAATAGTAGCAATTACTGCTG-30 and
SpyT_lnk_STh_R: 50-gtcggcttgtaagcgtccaccattacaatgtgagcCTGAAAA
TAAAGATTCTCGC-30. The bases encoding the SpyTag and linker
are shown in lower case, while the upper-case bases match the
vectors. The first residue of the SpyTag was positioned immedi-
ately downstream of a Tobacco Etch Virus protease (TEV) cleavage
sequence, thus exploiting TEV’s flexibility in the P’1 position,
allowing enzymatic release of SpyTag-ST fusion peptides no extra
amino acids [37]. The resulting expression vectors, pET-DsbC-
SpyT-STh and pET-DsbC-SpyT-A14T, were verified by sequencing.
The SpyTag-STh and SpyTag-STh-A14T fusion peptides, named
SpyT-STh and SpyT-A14T, were produced by adapting our previ-
ously described system for expressing and purifying native ST
and ST mutants [20]. In brief, chemically competent E. coli BL21
StarTM (DE3) (Invitrogen, Waltham, MA, USA) were transformed
with pET-DsbC-SpyT-STh or pET-DsbC-SpyT-A14T, plated on LB-
Agar supplemented with 50 mg/mL kanamycin, followed by incuba-
tion at 37 C overnight. Single colonies were used to inoculate 5 mL
Luria-Bertani (LB) growth medium supplemented with 50 mg/mL
kanamycin, and incubated overnight at 37 C and 200 rpm using
a 25 mm throw. One mL overnight culture was used to inoculate
1 L Yeast Extract Tryptone (2X YT) broth supplemented with 2%
glucose (w/v) and 50 mg/mL kanamycin. The culture was grown
at 37 C and 200 rpm using a 25 mm throw. When the optical cell
density reached 0.6 at 600 nm the protein expression was induced
by adding IPTG to a final concentration of 500 mM and the temper-
ature was lowered to 18 C before overnight expression.
Cells were harvested by centrifugation at 8,000  g for 20 min
followed by re-suspension in 10 mL lysis buffer (50 mM Tris-HCl,
300 mM NaCl, 20 mM Imidazole, 0.2% Triton X-100, 1 mg/mL lyso-
zyme [pH 8]) per gram wet weight pellet. After 30 min incubation
on ice, the bacteria were sonicated using an Ultrasonic homoge-
nizer (Cole-Parmer Instrument Co., Vernon Hills, IL, USA) followed
by clarification of the lysate at 20,000  g for 20 min.
The lysate was loaded onto 5 mL HisTrap FF Crude Ni-NTA col-
umns (GE Healthcare Life Sciences, Chicago, IL, USA) connected to
an ÄKTA pure system (GE Healthcare Life Sciences). The bound
peptides were washed in buffer A (50 mM Tris-HCl, 300 mM NaCl,
20 mM Imidazole [pH 8]) followed by elution in buffer B (50 mM
Tris-HCl, 300 mM NaCl, 500 mM Imidazole [pH 8]). To cleave off
the SpyT-tagged STs, we first performed a buffer exchange to TEV
cleavage buffer (20 mM NaPi, 125 mM NaCl [pH 7.4]) using PD-
10 desalting columns (GE Healthcare Life Sciences). To allow for
TEV cleavage under non-reducing conditions, [38] glutathione
(GSH) and glutathione disulfide (GSSG) (Sigma-Aldrich, St. Louis,
MO, USA) was supplemented to final concentrations of 0.6 mM
and 0.4 mM, respectively, after the buffer exchange.
After adding 1:30 M ratio of His-tagged TEV protease and incu-
bating overnight at room temperature, the solution was passed a
second time over a Ni-NTA agarose resin gravity column (Qiagen,
Hilden, Germany) to bind and remove DsbC, uncleaved fusion pro-
tein and TEV. The flow through was collected and concentrated
using 3 kDa cut-off AmiconTM Ultra-15 centrifuge filters (Merck
Millipore, Burlington, MA, USA) before being loading onto a Super-
dex 30 PG HiLoad 16/600 size exclusion column (GE healthcare life
sciences), operated by an ÄKTA pure system. Purified SpyT-STh and
SpyT-A14T were eluted in phosphate buffer saline (PBS; 1.8 mM
KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl [pH 7.4]) fol-
lowed by peptide concentration by using 3 kDa cut-off AmiconTM
Ultra-15 centrifuge filters. The purified proteins were analysed
on both SDS-PAGE (4–20% Mini-PROTEAN TGXTM Precast Protein
Gels (Bio-Rad, Hercules, CA, USA) and by MALDI-TOF/TOF mass
Fig. 1. Design and production of SpyT-STh, SpyT-A14T, AP205-SpyC, and the AP205-SpyC:SpyT-STh and AP205-SpyC:SpyT-A14T immunogens. (A) Illustration of the DsbC-
His-TEV-SpyT-STh fusion protein. Linker sequences are shown in white, while His-tags and TEV cleavage sites are shown as cross- and horizontal-hatched regions,
respectively. The sizes and molecular masses of the full-length fusion protein and the retrieved products after TEV protease cleavage are indicated with horizontal bars. The
amino acid sequence of the SpyTag-linker-STh fusion protein is also shown, and the separations of the three regions are indicated by vertical lines, together with a ‘T’ which
indicates the position of the A14T mutation. (B) Illustration of the AP205-SpyC fusion protein. The linker and His-tag are shown as white and cross-hatched regions,
respectively. (C) SDS-PAGE gel showing purified SpyT-STh (lane 1), purified SpyT-A14T (lane 2), and a molecular marker (Mm). (D) SDS-PAGE gel showing purified AP205-
SpyC proteins (lanes 1 and 3), purified AP205-SpyC:SpyT-STh conjugates (lane 2), purified AP205-SpyC:SpyT-A14T (lane 4) conjugates, and a molecular marker (Mm).
M.L. Govasli et al. / Vaccine 37 (2019) 6405–6414 6407spectrometry by using an ULTRAFLEX II (Bruker Daltonics, Bremen,
Germany) as previously described [20].2.2. Antigenicity of purified SpyT-STh and SpyT-A14T
The antigenicities of SpyT-STh and SpyT-A14T were analysed in
both a monoclonal and a polyclonal competitive ELISA as described
previously [17]. In brief, the ELISAs were performed by coating the
wells of Nunc Immobilizer Amino Plates (Thermo Fisher Scientific,
Waltham, MA, USA) with 0.11 mg STh-ovalbumin conjugates in
100 mL ELISA PBS buffer (3.25 mM Na2HPO4, 9.6 mM NaH2PO4,
146 mM NaCl [pH 7.4]) overnight at 4 C. The wells were then
emptied and blocked by adding 180 mL ELISA PBS-T (3.25 mM Na2-
HPO4, 9.6 mM NaH2PO4, 146 mM NaCl, 0.05% (v/v) Tween-20, [pH
7.4]) containing 1% (w/v) ovalbumin and incubated for 1 h at room
temperature with gentle shaking. Following 3 washes with ELISA
PBS-T, we added 60 mL SpyT-STh, SpyT-A14T, or native STh that
had been diluted 12 times 3-fold from 10 mM in ELISA PBS-T. We
then added 60 mL 1:15,000 diluted anti-STp C30 mAb (Clone
M120530; Fitzgerald, North Acton, MA, USA), which is an ST-
neutralizing mAb that recognizes an epitope centred around Y19
in native STh [18], or 60 mL 1:4,000 diluted ST-neutralizing poly-
clonal anti-STh antibody, which was kindly provided by John D.
Clements at Tulane University, that has been generated by immu-
nizing rabbits with a bovine serum albumin (BSA)-STh conjugatefollowed by Protein A purification of the resulting serum. After
2 h of incubation with gentle shaking at room temperature, we
washed the plates 3 times with ELISA PBS-T before adding 100 mL
1:4000 diluted anti-mouse IgG antibody conjugated to alkaline
phosphatase (Product code: ab6729, Abcam, Cambridge, United
Kingdom). After 1 h incubation at room temperature and 3 subse-
quent washes with ELISA PBS-T, we added 100 mL developing
reagent (250 mM diethanolamine, 0.5 mM MgCl2, 0.5 mg/mL 4-
Nitrophenyl phosphate disodium salt [pH 9.8]) and measured the
absorbance at 405 nm at a time when the well with the strongest
signal had an absorbance between 1.0 and 2.0 in a Hidex Sense
microplate reader (Hidex, Turku, Finland).2.3. AP205-SpyC expression, purification, and VLP production
The pKB_215 - 6xHIS-SpyCatcherDN1-CP3 plasmid encoding
the SpyCatcher coupled to the AP205 coat protein (AP205-SpyC)
was a kind gift from Mark Howarth and Karl D. Brune, University
of Oxford. The expression and purification of AP205-SpyC was per-
formed as previously described [35], but with a few modifications.
The plasmid was transformed into the chemically competent E. coli
strain OverExpressTM C41(DE3) (Lucigen, Middleton, WI, USA) and
plated on LB-Agar supplemented with 100 mg/mL ampicillin. Fol-
lowing overnight incubation at 37 C, 4 individual colonies were
added to 500 mL 2xYT broth containing 20 mg/mL ampicillin. After
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500 mL fresh 2xYT broth, and fresh ampicillin to a final concentra-
tion of 20 mg/mL (assuming the previously added ampicillin had
been degraded), was added before continuing the incubation at
100 rpm shaking. When the optical density at 600 nm reached
0.5–0.7 the temperature was reduced to 22 C, and after 30 min
IPTG was added to a final concentration of 500 mM for overnight
expression at 200 rpm using a 25 mm throw.
Cells were harvested by centrifugation at 5500  g for 15 min at
4 C. For each litre culture, the obtained bacterial pellet was resus-
pended in 10 mL lysis buffer (20 mM Tris-HCl, 150 mM NaCl,
75 mM Imidazole, 0.1% Triton X-100, 0.1% Tween-20, 25 U/mL Ben-
zonase Nuclease (Merck Millipore), 0.2 mg/mL lysozyme, 1x cOm-
pleteTM, EDTA-free Protease Inhibitor Cocktail (Roche, Mannheim,
Germany) [pH 7.8]). Following 10 min incubation at room temper-
ature, the resuspended cells were frozen at 80 C for 30 min
before thawing and sonication using an Ultrasonic homogenizer
(Cole-Parmer Instrument Co.). The lysate was then cleared by cen-
trifugation at 15,000  g for 20 min at 4 C, moving the super-
natant to a fresh tube, repeating the centrifugation, and then
passing the supernatant through a 0.4 mm WhatmanTM Nucleopore
Polycarbonate filter (GE Healthcare Life Sciences) and incubation in
room temperature for 5 min after adding 250 U Benzonase Nucle-
ase (Merck Millipore). For each litre initial culture, the lysate was
mixed with 400 mL Ni-NTA agarose (Qiagen) that had been equili-
brated with 20 mM Tris-HCl, 150 mM NaCl, 75 mM imidazole
[pH 7.8]. After 10 min incubation at 4 C, the Ni-NTA agarose con-
taining the bound AP205-SpyC was transferred to a 10 mL Econo-
Pac polypropylene column (Bio-Rad). The flow through was
allowed to pass through the column, collected and loaded onto
the column once more before washing the column with 3
column-volumes of Washing buffer (20 mM Tris-HCl, 150 mM
NaCl, 100 mM imidazole [pH 7.8]) followed by elution using elu-
tion buffer (50 mM glycine, 25 mM sodium citrate, 2 M Imidazole,
0.1% (v/v) tween-20 [pH 8.5]). 1 mL fractions were collected and
analysed by SDS-PAGE, and the fractions containing AP205-SpyC
at high concentrations were pooled and dialyzed by using a
300 kDa cut-off membrane (Spectrum Laboratories, Rancho Dom-
inguez, CA, USA) against Dialysis buffer (50 mM glycine, 25 mM
sodium citrate, 0.1% (v/v) tween-20 [pH 8]). The A205-SpyC mono-
mers self-assemble into VLPs and the dialysis allows for small non-
VLP proteins to escape while the high molecular weight VLPs are
retained.
2.4. AP205-SpyC:SpyT-ST VLP production
Conjugation of SpyT-STh and SpyT-A14T to the AP205-SpyC
VLPs was achieved by simply mixing AP205-SpyC VLPs with
SpyT-STh or SpyT-A14T in a 1:2 M ratio to assemble AP205-SpyC:
SpyT-STh and AP205-SpyC:SpyT-A14T VLPs. The conjugation was
performed overnight at room temperature in Dialysis buffer and
conjugation was monitored by SDS-PAGE.
Following conjugation, unbound SpyT-STh or SpyT-A14T was
removed by dialysis by using a 300 kDa cut-off membrane (Spec-
trum Laboratories), followed by centrifugation at 17,000  g for
30 min at 4 C to remove any protein aggregates. To remove any
co-purified endotoxins, the conjugates were filtered through a
0.2 mm PTFE WhatmanTM filter and endotoxins were removed by
using a Triton X-114-based phase separation method as described
previously [39]. The endotoxin levels of the cleaned VLP conjugates
were below 1 endotoxin units (EU) per mL, as determined by using
the PierceTM LAL Chromogenic Endotoxin Quantitation Kit (Thermo
Fisher Scientific). The VLP conjugates were then kept at 4 C, and all
subsequent procedures were performed by using endotoxin-free
certified consumables. The ST-conjugated VLP capsid protein con-
centrations were measured by using the Pierce BCA Protein AssayKit (Thermo Fisher Scientific) and subsequently diluted to 300
mg/mL in Endotoxin-free Dialysis buffer (50 mM glycine, 25 mM
sodium citrate, 0.1% (v/v) Tween 20 [pH 8.0]).
2.5. Immunizations
Immunizations and serum collection were performed by Gen-
Script (Piscataway, NJ, USA). Five age-matched, 9 week old, female
BALB/C mice were immunized with AP205-SpyC:SpyT-STh, five
were immunized with AP205-SpyC:SpyT-A14T, and five control
mice were immunized with molar equivalents of unconjugated
SpyT-STh. The mice received the primary immunization and boos-
ter immunizations on day 14 intramuscularly in the rear leg with
100 mL doses that contained the equivalent of 1 nmol (2 mg) ST pep-
tide. This implies that estimated total immunogen doses of AP205-
SpyC:SpyT-STh and AP205-SpyC:SpyT-A14T were 28 mg, and that
of SpyT-STh was 4.3 mg. No adjuvants were used, pre-
immunization sera were collected for all the mice, and the mice
were sacrificed and sera were collected on day 28.
2.6. Estimation of endpoint serum antibody titers by ELISA
Serum samples from each immunized mouse were titrated for
anti-STh and anti-AP205-SpyC IgG antibodies in ELISA assays. After
coating the wells of Nunc Immobilizer Amino plates overnight with
40 ng native STh in 100 mL ELISA PBS buffer or 100 ng AP205-SpyC
in 100 mL coating buffer (15 mM sodium carbonate, 35 mM sodium
bicarbonate), we emptied the wells and added 120 mL mouse
serum that had been serial diluted 2-fold from 1:1000 to
1:2,048,000 in ELISA PBS buffer. Following incubation for 1 h at
room temperature, 3 washes with PBS-T, 1 h incubation with
100 mL anti-mouse IgG antibody conjugated to alkaline phos-
phatase (Abcam), and 3 washes with PBS-T, we added 100 mL
Diethanolamine buffer and read the absorbance at 405 nm on a
Hidex Sense microplate reader (Hidex). The titer was defined as
the highest dilution that gave a signal over background ratio
of  2.1.
2.7. Analysis of immunological cross-reactivity by competitive ELISA
To measure the reactivity between mouse serum antibodies and
native STh, STp, guanylin, and uroguanylin, we used competitive
ELISAs as described previously [17]. The competitive ELISAs were
performed as described above, but with the following modifica-
tions. In these assays, we coated the plates with 4 ng native STh
per well, and we used STh, STp, guanylin, and uroguanylin that
had been diluted 3-fold 12 times from 10 mM to outcompete the
mouse serum antibody binding to the immobilized STh. Each
serum sample was analysed three times in independent
experiments.
2.8. T84 cell toxicity assay
The T84 cell toxicity assay was performed as described previ-
ously [17]. Briefly, T84 cells (ATCC, Rockville, MD, USA) were
seeded and grown to confluence in Nunc 24-well plates (Thermo
Fisher Scientific) containing GibcoTM Dulbecco’s Modified Eagle
Medium/Nutrient Mixture F-12 (DMEM/F-12; Thermo Fisher Sci-
entific) supplemented with 10% foetal bovine serum (Sigma-
Aldrich) and 0.2% gentamicin (LONZA, Basel, Switzerland). Cells
were washed thrice with 500 mL DMEM/F-12 and incubated with
200 mL DMEM/F-12 containing 1 mM 3-isobutyl-1-
methylxanthine (Sigma-Aldrich) for 10 min at 37 C in 5% CO2.
The toxicity assays were performed in three independent experi-
ments. The peptides to be tested were first serially diluted, 5 times
2-fold from 1 lM, in 200 lL DMEM/F-12 medium before being
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5% CO2, the medium was aspirated and cells were lysed by adding
500 mL 0.1 M HCl and incubated at 20 C for 20 min. The lysates
were then cleared by centrifugation at 16,000  g for 10 min and
cGMP levels in the resulting supernatants were determined using
a cGMP enzyme immunoassay kit (Enzo Life Sciences Inc., Farm-
ingdale, NY, USA) according to the manufacturer’s instructions.
2.9. T84 cell neutralization assay
To measure to what extent the mouse serum antibodies could
neutralize the toxic activity of native STh, we diluted the serum
to 1:5, 1:10, 1:100, and 1:1000 in DMEM/F-12 medium, added
native STh to 40 nM, and incubated the solutions overnight at
4 C. The samples were then tested in the T84 cell assay as
described above. These analyses were repeated in three indepen-
dent experiments.
2.10. Data and statistical analyses
GraphPad Prism 8 (GraphPad Software, La Jolla, CA) was used
for plots and regression analyses. Analyses of competitive ELISAs
using four-parameter log-logistic regression were performed as
previously described [19], using the following constraints: the bot-
tom parameter was a shared value for all data sets, and the top
parameter was set to a maximum value of 100. To test whether dif-
ferences between the 50 percent inhibitory concentration (IC50)
mean values of SpyT-STh and SpyT-A14T were statistically differ-
ent to that of the control STh, we used ordinary one-way analysis
of variance (ANOVA), and corrected for multiple testing using Dun-
net’s test. Cross-reacting fractions were calculated for STp, urogua-
nylin, and guanylin, also as previously described [19]. Briefly, using
the same constraints as above, four-parameter log-logistic regres-
sion models were generated using the R statistical computing envi-
ronment and the drc R package [19,40]. The fitted models were
used to calculate the 90 percent inhibitory concentrations (IC90)
for STh, which were used to calculate the percent inhibition of
binding for each of the other peptides at the IC90 of STh. The esti-
mated values were adjusted by subtracting the bottom parameter
estimate, and cross-reacting fractions were calculated by dividing
the adjusted percent inhibition value of each peptide by the corre-
sponding inhibition values for STh.3. Results and discussion
3.1. Expression and purification of STh and STh-A14T genetically fused
to SpyTag
To investigate the potential of VLPs for making ST immuno-
genic, we chose to use the newly developed AP205 VLP system,
where the AP205 protein has been genetically fused to a Spy-
Catcher domain [35]. A prerequisite for coupling heterologous pro-
teins to AP205 using this system is to genetically fuse the desired
protein to a SpyTag peptide. Hence, we fused both native STh
and STh-A14T to the C-terminus of the SpyTag, separated by a
spacer (Fig. 1A). The two fusion peptides were named SpyT-STh
and SpyT-A14T, respectively. To express the fusion peptides in
E. coli, we adopted our previously published recombinant ST purifi-
cation system [20]. The SpyT-STh and SpyT-A14T peptides were
genetically fused to the C-terminus of the disulfide isomerase DsbC
linked by a His-tag for purification and a TEV protease cleavage site
for the release of free fusion peptide (Fig. 1A). DsbC assists in the
formation of the three disulfide bridges of ST, which is necessary
for correct folding. After purification SpyT-STh and SpyT-A14T pep-
tides were concentrated and analysed by SDS-PAGE (Fig. 1C).Although SDS-PAGE analyses of the purified SpyT-STh and SpyT-
A14T peptides indicated sizes > 4.3 kDa (Fig. 1C), an immunoblot
using the C30 mAb confirmed that the band on the gel contained
ST (not shown). Moreover, mass spectrometry analysis confirmed
that the purified peptides indeed were SpyT-STh and SpyT-A14T.
Assuming both peptides have 6 oxidized cysteines, representing
3 disulfide bonds, the theoretical monoisotopic masses for the
SpyT-STh and SpyT-A14T are 4284.74 and 4314.75 Da, respec-
tively. We measured the peptides to be 4284.75 Da and
4315.09 Da, respectively. This indicates that the purified peptides
had intact disulfide bridges, which is a requirement for correct
folding.
3.2. Biological activity and antigenicity of SpyT-STh and SpyT-A14T
Coupling ST to a protein carrier by chemical conjugation has
been reported to significantly reduce its toxicity [41]. To assess
the impact of the SpyTag and linker peptide on the biological activ-
ity of STh, we compared the toxicity of SpyT-STh and SpyT-A14T
with that of native STh in the T84 cell assay (Fig. 2A). SpyT-STh
had somewhat lower toxicity than native STh, whereas SpyT-
A14T which is based on the STh-A14T mutant with >800-fold
reduced toxicity [20], had no detectable toxicity. The reduced tox-
icity of SpyT-STh may be attributed to steric hindrance by the fused
SpyTag and linker peptides and/or to the presence of SpyT-STh iso-
mers with alternative disulfide bridge configurations [20].
The structure of ST variants made immunogenic through
genetic fusions or chemical conjugations should be as close as pos-
sible to that of native ST, to ensure that protective epitopes are
intact and to maximize the likelihood of eliciting antibodies that
neutralize native ST. We used the neutralizing C30 monoclonal
anti-STp antibody that recognizes an epitope centered around
Y19 [18], and a neutralizing polyclonal anti-STh antibody to com-
pare the epitope repertoire of SpyT-STh and SpyT-A14T with that
of native STh in competitive ELISAs. The abilities of SpyT-STh and
SpyT-A14T to inhibit the monoclonal antibody binding to immobi-
lized native STh was 4.2-fold (mean difference 13 nM, P = 0.0001)
and 2.3-fold (mean difference 5 nM, P = 0.0001) lower than that
of native STh (Fig. 2B). SpyT-STh and SpyT-A14T also had 5.0-fold
(mean difference 12 nM, P = 0.001) and 1.3-fold (mean difference
0.8 nM, P = 0.6) reduced ability, respectively, to inhibit binding of
the polyclonal antibody (Fig. 2C). We cannot rule out partial mask-
ing of epitopes by the SpyTag, but overall, the results suggest that
the epitope repertoires of SpyT-STh and SpyT-A14T are largely
shared with that of STh.
3.3. Conjugation of SpyT-STh and SpyT-A14T to AP205-SpyC
The AP205-SpyC VLP scaffold (Fig. 1B) was expressed and puri-
fied as previously described [35]. The A205-SpyC monomers self-
assemble into VLPs, and extensive dialysis using a 300 kDa cutoff
membrane allows small non-VLP proteins to escape while retain-
ing the high molecular weight VLPs. SDS-PAGE analysis of the
AP205-SpyC VLPs displayed only one visible band, migrating close
to the expected molecular monomer mass of 25.8 kDa, suggesting
high purity (Fig. 1D).
To prepare the immunogens, AP205-SpyC was mixed separately
with SpyT-STh or SpyT-A14T at 1:2 M ratios, and unbound pep-
tides were removed by dialysis using a 300 kDa cutoff membrane.
SDS-PAGE analysis revealed only one band for each of the conju-
gates, migrating close to the expected molecular mass of
29.1 kDa (Fig. 1D). This suggest that the spontaneous isopeptide
bond conjugation reaction was efficient, and that the resulting
VLPs have hapten-carrier ratios that approach the theoretical num-
























































































Fig. 2. Toxicity and antigenicity of SpyT-STh and SpyT-A14T (A) T84 cell toxicity assays, where a dilution series of equimolar amounts of SpyT-STh (red), SpyT-A14T (blue)
and native STh (black) were tested for the ability to induce cellular cGMP. The error bars indicate the standard deviations from three independent experiments. Note that
SpyT-A14T did not induce any noticeable cGMP production and its values are therefore, not clearly visible. (B) and (C) show results from the antigenicity testing of SpyT-STh
and SpyT-A14T. Competitive ELISAs were used to investigate the ability of equimolar amounts of SpyT-STh (red), SpyT-A14T (blue), and native STh (black) to outcompete
binding of (B) the anti-STp monoclonal antibody C30 and (C) a polyclonal anti-STh antibody to immobilized STh. Each data point represents the mean from three independent
assays, and the error bars, representing standard deviations, are shown where they exceed the size of the data point symbol. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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We immunized five mice each with AP205-SpyC:SpyT-STh and
AP205-SpyC:SpyT-A14T VLPs, as well as five mice with the SpyT-
STh peptide alone as a control. The pre-immune sera from all mice
used in the immunizations, as well as the endpoint sera for the
mice immunized with SpyT-STh alone, had no detectable anti-
STh or anti-AP205-SpyC serum IgG antibodies, at the highest con-
centration tested which was a 1:1000 dilution of the sera. The lack
of an anti-STh immune response from the mice immunized with
SpyT-STh suggest that the SpyT-STh itself is not immunogenic.
The endpoint sera from the mice immunized with AP205-SpyC:
SpyT-STh and AP205-SpyC:SpyT-A14T all displayed high titers,
ranging from 4000 to 32,000 for anti-STh (Fig. 3A) and 64,000 to
512,000 for anti-AP205-SpyC (Fig. 3B). Interestingly, the mean
anti-ST titers of sera from mice vaccinated with AP205-SpyC:
SpyT-STh (mean titer: 18,400) were similar to those frommice vac-
cinated with AP205-SpyC:SpyT-A14T (mean titer: 16,000), indicat-
ing that the A14T mutation does not have a major negative impact
on the quality of the anti-STh immune response, which makes STh-
A14T a promising antigen for use in ST-based vaccines.3.5. Serum antibody STh-neutralization
To assess whether the serum antibodies from mice immunized
with AP205-SpyC:SpyT-STh and AP205-SpyC:SpyT-A14T are able
to neutralize the toxic activity of native STh, we tested the serain T84 cell neutralization assays. When diluted 1:5, sera from both
groups of mice almost completely inhibited STh-induced cGMP
production, suggesting the sera contained antibodies that effec-
tively neutralize STh (Fig. 4). Diluting the sera 1:10 and 1:100-
fold gave only partial neutralization, and no or very little neutral-
ization could be seen when diluting the sera 1:1000. Interestingly,
there appeared to be very little variation in these neutralization
estimates, both within and between groups. This is in contrast to
a study of STh- and STp-bovine serum albumin conjugates, where
the ST-neutralizing immune responses varied both between and
within immunization groups [19]. Although further studies are
needed to identify the underlying cause of the lower variability,
we suspect the homogeneous and orderly presentation of STs on
the surface of the VLPs, in addition to the omission of additional
adjuvants result in a more predictable immune response than
more traditional formulations. In addition, the finding that the
STh neutralization abilities of sera from mice immunized with
the STh-A14T antigens appeared to match those from mice immu-
nized with native STh antigens suggest that the A14T mutation
does not impair the ability to elicit STh-neutralizing antibodies.3.6. Immunological cross-reactivity
STh and STp are very similar both in sequence and structure:
their sequences are 78% identical, and 4 of the 5 amino acid differ-
ences are found in the N-terminus [12]. This implies that the two




























































































Fig. 3. Endpoint serum antibody titers. The endpoint sera from ten mice were titrated in ELISAs where STh (A) or AP205-SpyC (B) was immobilized on ELISA plates and an
anti-mouse IgG antibody was used to detect bound anti-STh and anti-AP205-SpyC antibodies from five mice immunized with AP205-SpyC:SpyT-STh (in red) and five mice
immunized with AP205-SpyC:SpyT-A14T (in blue). The titers were defined as the highest dilutions that had signal over background ratios of  2.1. Each data point represents
the mean antibody titer from three independent ELISAs, and the horizontal lines represent the mean of these titers from all five mice. (For interpretation of the references to




























































Fig. 4. Serum STh neutralization. Dilutions of endpoint sera were tested for their ability to neutralize native STh in T84 cell neutralization assays. The data points represent
the mean result from three independent experiments with sera from 5 mice (M1 to M5) immunized with (A) AP205-SpyC:SpyT-STh (in red) or with (B) AP205-SpyC:SpyT-
A14T (in blue). The error bars, which indicate the standard deviation based on results from three independent experiments, are shown where they exceed the size of the data
point symbols. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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STp and offer protection against STp-producing ETEC strains. The
endogenous GC-C receptor activating peptides, uroguanylin and
guanylin, are also similar to the ST toxins, with 69% and 53%
sequence identity to STh, respectively [12]. Potential interference
with the natural regulation of the GC-C receptors could occur if
an ST-based vaccine elicits antibodies that cross-react strongly
with guanylin or uroguanylin. To study both wanted (STp) and
unwanted (uroguanylin and guanylin) immunological cross-
reactions from immunizations with STh-based antigens, we per-
formed competitive ELISAs where we tested the ability of native
STh, STp, guanylin and uroguanylin to compete with the coated
STh for binding to the antibodies present in the mouse sera
(Fig. 5). As expected, STh completely outcompeted binding of
anti-STh antibodies to the STh coating at the highest concentra-
tions, and STp was almost as efficient in doing so, suggesting strong
cross-reaction to STp (Fig. 5A). The same pattern was also observed
with the anti-STh-A14T antibodies (Fig. 5B). In contrast, for all sera
tested, there seemed to be low levels of antibodies cross-reacting
with uroguanylin and guanylin (Fig. 5A and B).For consistent comparisons of immunological cross-reactivity
between sera, we used the 90 percent inhibitory concentration
(IC90) of STh as a common reference point (Fig. 5A and B). For each
peptide, the cross-reacting fraction of antibodies was calculated by
dividing the percent inhibition of each peptide at the reference
concentration with that of STh (Fig. 5C). For the anti-STh sera,
the median cross-reacting fraction for STp was 0.87 (range 0.67–
0.93), and for the anti-STh-A14T sera, it was 0.76 (range 0.68–
0.81). For uroguanylin, the median cross-reacting fractions were
0.10 (range 0.2–0.11) and 0.12 (range 0.8–0.15), respectively, and
for guanylin they were 0.08 (range 0.4–0.11) and 0.06 (range
0.05–0.12), respectively. This contrasts to what was previously
observed in serum samples from mice that had been subcuta-
neously immunized with adjuvanted solutions of STh- and STp-
bovine serum albumin conjugates [19]. In that study, much higher
levels of cross-reacting antibodies to both uroguanylin and
guanylin were observed in individual mice, with maximum
cross-reacting fractions of 0.55 and 0.42, respectively. The differ-
ence in cross-reacting immune responses between the two studies
could be an effect of differences in antigen presentation, route of



























































































































































































































































































Fig. 5. Immunological cross-reactivity. (A) Cross-reactivity of sera from the five mice immunized with AP205-SpyC:SpyT-STh (one graph per mouse, labelled M1 to M5). The
sera were mixed with STh (red), STp (purple), guanylin (blue), or uroguanylin (orange) in a competitive ELISA to evaluate to what extent these peptides could outcompete
binding of serum antibodies to immobilized STh. Each data point represents the mean of three independent experiments, the error bars, which are shown where they exceed
the size of the data point symbol, represent the standard deviations, and the graph lines are regression curves generated by four-parameter logistic regression analyses.
Peptide concentrations are plotted on a logarithmic scale on the horizontal axis, and the vertical axis shows percent inhibition, which is given as a percentage of the
maximum binding of the serum antibodies measured in the absence of a competing peptide. The dotted line represents the 90 percent inhibitory concentration (IC90) of STh.
(B) Cross-reactivity of sera from the five mice immunized with AP205-SpyC:SpyT-A14T (one panel per mouse, labelled M1 to M5). The assay and analysis were performed as
in (A). (C) Assessment of cross-reactive fractions at IC90 of STh. For each serum, four-parameter logistic regression was performed, and the IC90 concentrations were calculated
for STh, and were used to calculate the cross-reacting fractions for each peptide relative to that of STh. The plot shows the inhibition relative to that of STh at IC90 for STh
(vertical axis) for each peptide (horizontal axis) in each serum (anti-AP205-SpyC:SpyT-STh in red, anti-AP205-SpyC:SpyT-A14T in blue), and the lines depict median cross-
reactive fractions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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M.L. Govasli et al. / Vaccine 37 (2019) 6405–6414 6413immunization, and/or the use of Freund’s adjuvant. The low level
of unwanted immunological cross-reactions observed in this study
is encouraging for the prospects of developing a safe ST-based
vaccine.4. Conclusions
VLPs are known to be highly immunogenic and are increasingly
being explored for use as carriers for presenting heterologous anti-
gens [25–28].Here,wehave for thefirst timeusedVLPs tomakeboth
native STh and the non-toxic mutant STh-A14T immunogenic. We
have shown that immunizing with the AP205-SpyC:SpyT-STh and
AP205-SpyC:SpyT-A14T VLPs consistently elicited anti-STh anti-
body responses in mice, that the resulting antibodies were able to
neutralize STh and STp, and that the immunization produced little
or no unwanted immunological cross-reaction to uroguanylin and
guanylin. This is also the first time immunizations with ST antigens
have given anti-ST immune responses without the use of adjuvants.
Although further studies are needed,we suspect the improved qual-
ity of the anti-ST immune responses may partially be a result of
omitting Freund’s complete and incomplete adjuvant from the vac-
cine formulations. In addition, the well-defined nature of VLPs
allows for heterologous antigens to be presented in a highly ordered
manner, which may have resulted in better inter-individual and
inter-group immune response consistencies both in terms of anti-
body titer, the ability to neutralize native STh, and in fewer and
lower levels of unwanted cross-reactive immune responses.
These encouraging results warrant further experiments. To
ensure consistent immune responses also in future experiments,
one must ensure that the STh-A14T-coupled AP205 VLPs forms
stable particles of uniform size. This can be addressed using meth-
ods such as electron microscopy and dynamic light-scatting analy-
sis. In addition, antigenicity studies using monoclonal antibodies
with known epitopes can be performed to identify exposed, and
possibly cross-reacting, epitopes [19]. In this first study using VLPs
to make native STh and the toxoid STh-A14T immunogenic, we
immunized mice intramuscularly and characterized serum IgG
responses. Protection against the ST toxin in vivo will require a
good mucosal immune response, and hence, future studies should
be expanded to also characterize faecal IgA antibody responses. To
ensure a good mucosal immune response, oral delivery of an ST
vaccine is a natural first choice. However, it has recently been
shown that the non-toxic double-mutant LT (dmLT), which is a
potent adjuvant, has the potential to elicit pathogen-specific
immunity in the intestinal tract with non-mucosal immunization
[42]. This is a highly attractive alternative for an ST vaccine for
two reasons. First, parenteral immunizations require substantially
less material than oral immunizations and parenteral vaccines
seem to be less prone to vaccine underperformance associated
with environmental enteropathy than oral vaccines [43]. Second,
administering an ST vaccine with dmLT as an adjuvant has the
potential of eliciting a complete anti-toxin immune response that
can protect against both ST and LT. It will be important to assess
whether the addition of an adjuvant, such as dmLT, to an ST-VLP
vaccine leads to increased immunological cross-reactivity towards
uroguanylin and guanylin. The importance of this is underscored
by the implication of these endogenous ligands in several diseases
and biological processes, including inflammatory bowel disease,
ulcerative colitis, colonic hypersensitivity, appetite regulation,
and attention deficit hyperactivity [19].
In conclusion, the results generated in this study suggest that
using VLPs is an attractive approach for making safe and effective
ST-based vaccines. Moreover, the results strongly suggest that
the mutant variant STh-A14T is an excellent candidate for an ETEC
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